Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM)): "LAVAL, QC, July 24 /PRNewswire-FirstCall/ - Neurochem Inc. announces that the U.S. Food and Drug Administration (FDA) has designated the investigational product candidate, tramiprosate (ALZHEMED(TM)), as a Fast Track Product for the treatment of Alzheimer's disease.
Under the FDA Modernization Act of 1997, the Fast Track designation program is intended to facilitate the development and expedite review of drugs developed for the treatment of serious or life-threatening conditions and that demonstrate the potential to address an unmet medical need for such a condition."
